Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$10.33 USD
+0.09 (0.88%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $10.45 +0.12 (1.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Adaptive Biotechnologies Corporation's return on equity, or ROE, is -62.79% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that ADPT has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ADPT 10.33 +0.09(0.88%)
Will ADPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADPT
Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?
What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
Other News for ADPT
COIN, BMNR, RBLX: Cathie Wood Buys Over $54M of Crypto Stocks, Dumps Roblox Stake
Adaptive Biotechnologies price target raised by $2 at BTIG, here's why
BTIG Increases Price Target for Adaptive Biotechnologies (ADPT) to $13
Aristotle Large Cap Growth Q2 2025 Commentary
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics